Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Authors :: Son Tran
Ritul Sharma
Chunfen Zhang
Ranjan Maity
Amy J. Johnson
Melanie M. Frigault
Raquel Izumi
Ahmed Hamdy
Beatrix Stelte-Ludwig
Nizar J. Bahlis
Paola Neri
Aru Narendran
Source :: Blood. 140:10685-10686
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools